Corbus Shares Tumble as Cancer Drug CRB-701 Shows Strong Phase 1/2 Results and $94.5M Raise

Introduction to Corbus Pharmaceuticals Holdings, Inc.

Corbus Pharmaceuticals Holdings, Inc. (Nasdaq: CRBP) is a clinical-stage biotechnology company headquartered in Norwood, Massachusetts. Founded in 2014, Corbus specializes in developing therapies in oncology and obesity using targeted drug modalities and immune-modulating approaches.

Corporate Structure and Experience

Corbus has a workforce of between 51 and 200 employees at its Norwood facility. The company’s pipeline includes three investigational therapies:

• CRB-701 (SYS6002), an antibody-drug conjugate targeting Nectin-4 in solid tumors
• CRB-601, a monoclonal antibody that inhibits TGF-β activation
• CRB-913, a peripherally restricted CB1 inverse agonist for obesity

Corbus collaborates with CSPC for the development of CRB-701 in China while managing U.S. and European studies internally.

Biotechnology by Louis Reed

Recent Developments and News

• On October 19, 2025, at the European Society for Medical Oncology (ESMO) Congress in Berlin, Corbus presented poster #967P, detailing Phase 1/2 clinical results for CRB-701. The 3.6 mg/kg dose achieved objective response rates of 47.6 percent in head and neck squamous cell carcinoma (HNSCC), 37.5 percent in cervical cancer, and 55.6 percent in metastatic urothelial carcinoma, along with a favorable safety and tolerability profile.
• In October 2025, Corbus priced a public offering of 4,973,750 shares at $19.00 per share, raising approximately $94.5 million before underwriting discounts and expenses. Lowenstein Sandler LLP served as legal counsel for the offering.
• On October 19, 2025, Corbus held an event featuring key opinion leaders to discuss updated data on CRB-701, with contributions from experts at the University of Chicago, Dana-Farber Cancer Institute, and Sarah Cannon Research Institute.

Financial and Strategic Analysis

As of October 30, 2025:

• Share price: $12.20, down 25.79 percent from the prior close of $16.86
• Trading volume: 267,622 shares
• 52-week range: $4.64 – $20.77
• Market capitalization: approximately $160 million
• Beta (5-year): 2.85

Trailing twelve-month metrics:

• Net loss: $57.95 million (diluted EPS: –4.76)
• Cash and equivalents: $116.59 million
• Total debt/equity: 2.21 percent
• Levered free cash flow: –$39.44 million
• Price/book ratio: 1.44

Analysts’ one-year consensus price target is $43.22.

Market Position and Industry Context

Corbus operates within the immuno-oncology and metabolic disease markets. Its ADC candidate, CRB-701, targets the Nectin-4 pathway, similar to therapies offered by other biotechnology companies. CRB-601’s anti-TGF-β mechanism aligns with ongoing efforts to enhance tumor immunogenicity. CRB-913 aims to offer a differentiated approach to obesity treatment through modulation of peripheral CB1 receptors. Strategic partnerships, such as the collaboration with CSPC in China, may enhance geographic expansion and resource utilization.

tl;dr

On October 31, 2025, CRBP shares traded at $12.20, down 25.79 percent from $16.86 on October 30, with a trading volume of 267,622 shares. On October 19, 2025, Corbus presented Phase 1/2 data for CRB-701 at ESMO, reporting response rates of 47.6 percent in HNSCC, 37.5 percent in cervical cancer, and 55.6 percent in metastatic urothelial carcinoma. In October 2025, the company raised $94.5 million through a public offering priced at $19.00 per share. With $116.59 million in cash, minimal debt, and three clinical-stage programs, Corbus has a one-year analyst price target of $43.22.